KNSA vs. EME
KNSA (Kiniksa Pharmaceuticals, Ltd.) and EME (EMCOR Group, Inc.) are both stocks. KNSA operates in Biotechnology (Healthcare), while EME operates in Engineering & Construction (Industrials). Over the past 5 years, KNSA returned 29.69%/yr vs 48.34%/yr for EME. At a 0.16 correlation, their price movements are largely independent.
Performance
KNSA vs. EME - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KNSA achieves a 33.60% return, which is significantly lower than EME's 36.89% return.
KNSA
- 1D
- 1.66%
- 1M
- 3.51%
- YTD
- 33.60%
- 6M
- 27.60%
- 1Y
- 93.78%
- 3Y*
- 52.43%
- 5Y*
- 29.69%
- 10Y*
- —
EME
- 1D
- 1.10%
- 1M
- -1.45%
- YTD
- 36.89%
- 6M
- 36.98%
- 1Y
- 72.81%
- 3Y*
- 68.65%
- 5Y*
- 48.34%
- 10Y*
- 33.87%
KNSA vs. EME - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
KNSA Kiniksa Pharmaceuticals, Ltd. | 33.60% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
EME EMCOR Group, Inc. | 36.89% | 35.05% | 111.27% | 46.03% | 16.81% | 39.93% | 6.47% | 45.18% | -21.78% |
Correlation
The correlation between KNSA and EME is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.16 |
Fundamentals
KNSA:
$4.54B
EME:
$37.69B
KNSA:
$0.92
EME:
$29.65
KNSA:
59.85
EME:
28.22
KNSA:
0.58
EME:
0.66
KNSA:
5.80
EME:
2.12
KNSA:
7.50
EME:
9.75
KNSA:
$754.05M
EME:
$17.75B
KNSA:
$294.06M
EME:
$3.47B
KNSA:
$101.06M
EME:
$2.03B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KNSA vs. EME — Risk / Return Rank
KNSA
EME
KNSA vs. EME - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and EMCOR Group, Inc. (EME). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KNSA | EME | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.38 | ||
| Sortino ratioReturn per unit of downside risk | +1.02 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.34 | +0.07 |
| Calmar ratioReturn relative to maximum drawdown | 4.63 | 2.91 | +1.73 |
| Martin ratioReturn relative to average drawdown | 16.35 | 7.10 | +9.25 |
Loading charts...
Drawdowns
KNSA vs. EME - Drawdown Comparison
The maximum KNSA drawdown since its inception was -83.06%, which is greater than EME's maximum drawdown of -70.56%. Use the drawdown chart below to compare losses from any high point for KNSA and EME.
Loading charts...
Drawdown Indicators
| KNSA | EME | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.06% | -70.56% | -12.50% |
Max Drawdown (1Y)Largest decline over 1 year | -21.12% | -25.15% | +4.03% |
Max Drawdown (3Y)Largest decline over 3 years | -34.14% | -36.19% | +2.05% |
Max Drawdown (5Y)Largest decline over 5 years | -53.17% | -36.19% | -16.98% |
Max Drawdown (10Y)Largest decline over 10 years | — | -48.00% | — |
Current DrawdownCurrent decline from peak | -7.35% | -11.35% | +4.00% |
Average DrawdownAverage peak-to-trough decline | -40.60% | -15.36% | -25.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.97% | 10.28% | -4.31% |
Volatility
KNSA vs. EME - Volatility Comparison
Kiniksa Pharmaceuticals, Ltd. (KNSA) and EMCOR Group, Inc. (EME) have volatilities of 10.40% and 9.99%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KNSA | EME | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.40% | 9.99% | +0.41% |
Volatility (6M)Calculated over the trailing 6-month period | 34.02% | 26.49% | +7.53% |
Volatility (1Y)Calculated over the trailing 1-year period | 43.03% | 38.67% | +4.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 53.48% | 33.40% | +20.08% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 63.93% | 33.05% | +30.88% |
Dividends
KNSA vs. EME - Dividend Comparison
KNSA has not paid dividends to shareholders, while EME's dividend yield for the trailing twelve months is around 0.16%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EME EMCOR Group, Inc. | 0.16% | 0.16% | 0.20% | 0.32% | 0.36% | 0.41% | 0.35% | 0.37% | 0.54% | 0.39% | 0.45% | 0.67% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
KNSA vs. EME - Financials Comparison
This section allows you to compare key financial metrics between Kiniksa Pharmaceuticals, Ltd. and EMCOR Group, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KNSA vs. EME - Profitability Comparison
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
EME - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, EMCOR Group, Inc. reported a gross profit of 863.95M and revenue of 4.63B. Therefore, the gross margin over that period was 18.7%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
EME - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, EMCOR Group, Inc. reported an operating income of 403.85M and revenue of 4.63B, resulting in an operating margin of 8.7%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
EME - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, EMCOR Group, Inc. reported a net income of 305.48M and revenue of 4.63B, resulting in a net margin of 6.6%.
Frequently Asked Questions
KNSA and EME have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KNSA has higher volatility (10.40%) compared to EME (9.99%). In terms of maximum drawdown, KNSA dropped -83.06% vs EME's -70.56%.
KNSA currently has the higher Sharpe Ratio (2.27 vs 1.89), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KNSA and EME
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer